Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Washington Post Column Examines Issues Surrounding Supreme Court Confirmation Hearings
"When a Supreme Court nominee such as Judge Sonia Sotomayor comes before the Senate for confirmation, she is promised a full, fair hearing," yet "every nominee"s path is booby-trapped by the history of previous confirmation battles," Washington Post columnist David Broder writes. Broder examines prior confirmation hearings, noting that the "[o]ne thing that may make it harder to forget the partisan and ideological battles of the past is that President Obama found reasons to oppose" Chief Justice John Roberts and Justice Samuel Alito while he was in the Senate.During Roberts" confirmation hearing, Obama said that although he was "sorely tempted to vote for Judge Roberts," he had issues with Roberts in cases where "precedent and rules of construction" are insufficient and where justice "can only be determined on the basis of one"s deepest values." Obama added that the rights of women and minorities are dependent on cases in which "the critical ingredient is supplied by what is in the judge"s heart." Obama said Roberts" record on women"s rights and other issues was not strong enough to quell doubts about Roberts" "deepest values."Broder continues, "Based on the Obama precedent, the White House can hardly complain if Republicans push beyond the question of Sotomayor"s qualifications and examine her values -- and her biases." He concludes, "Someday, the Senate may again be satisfied to examine only professional credentials, recognizing the uncertain dynamics of a nine-person bench," but while past precedents survive, "that is not likely" (Broder, Washington Post, 6/4).
generic viagra online
Terrence Higgins Trust's One-hour 'Fastest' Service Aims To Reduce Undiagnosed HIV In Tower Hamlets
In a bid to reduce levels of undiagnosed HIV, HIV and sexual health charity Terrence Higgins Trust (THT), Positive East and NHS Tower Hamlets are encouraging people who may have been at risk to attend a local service offering fast HIV testing. A "Fastest" clinic runs at Mile End Road every Tuesday from 6pm-9pm and there is also a monthly mobile clinic at venues across the borough.
News of the day
Fat Tissue Growth In Rodent Models Suppressed By Turmeric Extract
Curcumin, the major polyphenol found in turmeric, appears to reduce weight gain in mice and suppress the growth of fat tissue in mice and cell models. Researchers at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University (USDA HNRCA) studied mice fed high fat diets supplemented with curcumin and cell cultures incubated with curcumin.
Nutrition

QuantRx Announces FluoroPharma To Present Phase I Study Results Of Novel Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) Tracer

QuantRx® Biomedical Corporation (OTCBB:QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, announced that its affiliate, FluoroPharma Inc., a company developing breakthrough PET molecular imaging agents, will present Phase I data relating to the safety, dosimetry, and pharmacokinetics in human subjects of BFPET, its novel 18-F labeled (PET) tracer for myocardial perfusion imaging, at the Society of Nuclear Medicine 2009 Annual Meeting in Toronto. The results of this study will be presented by Dr. David Elmaleh, Director of Contrast Media Chemistry at the Massachusetts General Hospital and Associate Professor at Harvard Medical School at the "New Tracers, New Agents and New Stressors" scientific session on Tuesday, June 16, 2009, from 1:15 p.m. - 1:30 p.m. (EDT). BFPET is 18-F labeled tetraphenylphosphonium compound, designed to assess mitochondrial damage and myocardial perfusion. Myocardial perfusion imaging is a standard test to assess coronary artery disease (CAD) with more than 9 million Americans undergoing the test annually. About QuantRx Biomedical QuantRx Biomedical Corporation (OTCBB: QTXB) is a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry. With synergistic expertise in the discovery of diagnostic platforms and the commercialization of products for use by healthcare professionals and consumers, QuantRx is focused on providing more accurate, reliable, and faster diagnoses that result in improved patient care. The QuantRx strategy targets significant market opportunities estimated to be in excess of $5 billion worldwide. The Company"s technology portfolio, with more than three dozen patents, patents pending and licensed patents, includes: (1) RapidSense® point-of-care testing products based on QuantRx core intellectual property related to lateral flow techniques for the consumer and healthcare professional markets; (2) PAD technology for over-the-counter applications, and the diagnosis and treatment of women"s health concerns and other medical needs, and (3) significant investments in: (a) genome-based diagnostic chips for the laboratory and healthcare professional markets; and (b) molecular imaging agents for positron emission tomography (PET) and fluorescence imaging, with initial application in cardiovascular disease, addressing significant unmet medical needs by providing clinicians with important tools for early discovery and assessment. FluoroPharma


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009